Matches in Wikidata for { <http://www.wikidata.org/entity/Q91682330> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q91682330 description "2019 թվականի մայիսի 10-ին հրատարակված գիտական հոդված" @default.
- Q91682330 description "artículu científicu espublizáu en mayu de 2019" @default.
- Q91682330 description "im Mai 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91682330 description "scientific article published on 10 May 2019" @default.
- Q91682330 description "wetenschappelijk artikel" @default.
- Q91682330 description "наукова стаття, опублікована 10 травня 2019" @default.
- Q91682330 name "Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma" @default.
- Q91682330 name "Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma" @default.
- Q91682330 type Item @default.
- Q91682330 label "Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma" @default.
- Q91682330 label "Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma" @default.
- Q91682330 prefLabel "Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma" @default.
- Q91682330 prefLabel "Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma" @default.
- Q91682330 P1433 Q91682330-8EC89069-2B1B-4E8E-9B29-582F04CA9831 @default.
- Q91682330 P1476 Q91682330-CB9B98EE-C772-42F1-8185-98EDD855BF27 @default.
- Q91682330 P2093 Q91682330-63635CD0-B213-4F3D-9664-87767786B45B @default.
- Q91682330 P2093 Q91682330-ED311C9D-E7F1-4FB3-AEBC-65D4A7411B0B @default.
- Q91682330 P304 Q91682330-4E166402-578F-4D6B-8357-80A26CAABAFC @default.
- Q91682330 P31 Q91682330-4A19DD66-5184-425B-9AF0-754EDF915684 @default.
- Q91682330 P31 Q91682330-51a109f7-ba99-4f08-9efa-652960bb2cca @default.
- Q91682330 P356 Q91682330-8594415F-8D74-45BD-BD2B-1BD570036362 @default.
- Q91682330 P433 Q91682330-82CFDCE6-C292-4C50-A5C0-30E19209B6FA @default.
- Q91682330 P478 Q91682330-BF426F9B-DA5D-4C78-8081-7D5E2D8504F3 @default.
- Q91682330 P50 Q91682330-9561ED28-EE1C-4291-A933-02D204ACC33C @default.
- Q91682330 P577 Q91682330-D5DB3282-5843-462B-A1CD-4EFBF3B91261 @default.
- Q91682330 P698 Q91682330-E4AA4D71-2AA8-4C26-A696-F577FFCBE89E @default.
- Q91682330 P921 Q91682330-29EA8F5F-808D-4596-BE7C-BEEA5AF71A14 @default.
- Q91682330 P921 Q91682330-48DEA6C3-3132-4B84-ACD0-13D8DF935123 @default.
- Q91682330 P921 Q91682330-EDEC0304-E344-469E-B491-11432FC42C5D @default.
- Q91682330 P356 CCO.2019.04.05 @default.
- Q91682330 P698 31280574 @default.
- Q91682330 P1433 Q27724839 @default.
- Q91682330 P1476 "Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma" @default.
- Q91682330 P2093 "Veronica Mollica" @default.
- Q91682330 P2093 "Vincenzo Di Nunno" @default.
- Q91682330 P304 "S21" @default.
- Q91682330 P31 Q13442814 @default.
- Q91682330 P31 Q871232 @default.
- Q91682330 P356 "10.21037/CCO.2019.04.05" @default.
- Q91682330 P433 "S1" @default.
- Q91682330 P478 "8" @default.
- Q91682330 P50 Q72107595 @default.
- Q91682330 P577 "2019-05-10T00:00:00Z" @default.
- Q91682330 P698 "31280574" @default.
- Q91682330 P921 Q1164529 @default.
- Q91682330 P921 Q13896859 @default.
- Q91682330 P921 Q19000948 @default.